Compile Data Set for Download or QSAR
Report error Found 64 Enz. Inhib. hit(s) with all data for entry = 12112
TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679732((12S,14S,E)-11-((5-methoxy-7-methyl-1H-indol-4-yl)...)
Affinity DataIC50: 83.7nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679761(US20240182503, Example 77)
Affinity DataIC50: 85.6nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679716((12S,14S)-11-((5-methoxy-7-methyl-1H-indol- 4-yl)m...)
Affinity DataIC50: 96nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679727(4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl- 1H-ind...)
Affinity DataIC50: 122nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679748(US20240182503, Example 64)
Affinity DataIC50: 127nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679725((12R,14R)-11-((5-methoxy-7-methyl-1H-indol- 4-yl) ...)
Affinity DataIC50: 129nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679756(US20240182503, Example 72)
Affinity DataIC50: 129nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679700(US20240182503, Comparative Example 1)
Affinity DataIC50: 135nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679728(4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl- 1H-ind...)
Affinity DataIC50: 138nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679749(US20240182503, Example 65)
Affinity DataIC50: 139nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679741(US20240182503, Example 57)
Affinity DataIC50: 153nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679722((12R,14R,E)-11-((5-methoxy-7-methyl-1H- indol-4-yl...)
Affinity DataIC50: 160nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679733((12S,14S,E)-11-((5-methoxy-7-methyl-1H-indol-4-yl)...)
Affinity DataIC50: 208nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679744(US20240182503, Example 60)
Affinity DataIC50: 231nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679720((12R,14R,E)-11-((5-methoxy-7-methyl-1H- indol-4-yl...)
Affinity DataIC50: 241nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679743(US20240182503, Example 59)
Affinity DataIC50: 244nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679760(US20240182503, Example 76)
Affinity DataIC50: 251nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679723((12S,14RS)-11-((5-methoxy-7-methyl-1H-indol- 4-yl)...)
Affinity DataIC50: 251nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679755(US20240182503, Example 71)
Affinity DataIC50: 258nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679704(US20240182503, Example 5)
Affinity DataIC50: 262nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679702(4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indo...)
Affinity DataIC50: 263nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679721((12R,14R,Z)-11-((5-methoxy-7-methyl-1H- indol-4-yl...)
Affinity DataIC50: 263nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679757(US20240182503, Example 73)
Affinity DataIC50: 271nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679711(US20240182503, Example 12)
Affinity DataIC50: 280nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679746(US20240182503, Example 62)
Affinity DataIC50: 293nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679738(US20240182503, Example 54)
Affinity DataIC50: 303nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679724((12R,14R)-11-((5-methoxy-7-methyl-1H-indol- 4-yl)m...)
Affinity DataIC50: 309nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679730((12S,14S)-11-((5-methoxy-7-methyl-1H-indol- (4-yl)...)
Affinity DataIC50: 311nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679705(US20240182503, Example 6)
Affinity DataIC50: 313nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679751(US20240182503, Example 67)
Affinity DataIC50: 330nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679745(US20240182503, Example 61)
Affinity DataIC50: 331nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679708(US20240182503, Example 9)
Affinity DataIC50: 342nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679759(US20240182503, Example 75)
Affinity DataIC50: 352nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679740(US20240182503, Example 56)
Affinity DataIC50: 375nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679706(US20240182503, Example 7)
Affinity DataIC50: 384nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679709(US20240182503, Example 10)
Affinity DataIC50: 384nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679701(US20240182503, Comparative Example 2)
Affinity DataIC50: 395nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679729((12S,14S)-N-(ethylsulfonyl)-11-((5-methoxy-7- meth...)
Affinity DataIC50: 396nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679707(US20240182503, Example 8)
Affinity DataIC50: 397nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679750(US20240182503, Example 66)
Affinity DataIC50: 411nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679754(US20240182503, Example 70)
Affinity DataIC50: 543nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679753(US20240182503, Example 69)
Affinity DataIC50: 581nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679731((12S,14S)-N-(isopropylsulfonyl)-11-((5- methoxy-7-...)
Affinity DataIC50: 649nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679752(US20240182503, Example 68)
Affinity DataIC50: 674nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679762(US20240182503, Example 78)
Affinity DataIC50: 731nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679726((12R,14R,Z)-11-((5-methoxy-7-methyl-1H- indol-4-yl...)
Affinity DataIC50: 1.06E+3nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679742(US20240182503, Example 58)
Affinity DataIC50: 1.06E+3nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679712(US20240182503, Example 13)
Affinity DataIC50: 1.11E+3nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679710(US20240182503, Example 11)
Affinity DataIC50: 1.20E+3nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetComplement Factor B/Cobra Venom Factor(Monocled cobra)
Alexion Pharmaceuticals

US Patent
LigandPNGBDBM679758(US20240182503, Example 74)
Affinity DataIC50: 1.25E+3nMAssay Description:CVF-Bb complex, prepared from purified cobra venom factor, (3 nM) is incubated with a compound of the disclosure at various concentrations for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

Displayed 1 to 50 (of 64 total ) | Next | Last >>
Jump to: